For decades, abnormal proteins called amyloid and tau were widely accepted as the cause of Alzheimer’s disease. These theories dominated the field of science and led people to believe that removal of the abnormal plaque formed by the proteins, could cure Alzheimer’s disease.
Clinical trials on Aducanumab as a beta-amyloid antibody did reduce beba-amyloid load in the brain. However, patients’ clinical cognitive impairment did not reduce correspondingly. It leads to the conclusion that Alzheimer’s disease is not merely the results of brain pathological changes, preventive actions seem to be the most advisable strategies for the management.
Pathologies Are Not Determinants of Cognitive Decline
According to the publication on two clinical-pathologic studies on a total of 856 deceased participants,  the common pathologic changes only accounted for less than a third of the cognitive decline. Much remains unexplained….